Trial Master File Rescue and Reconstruction for Multi-Site Paper-Based Medical Device Clinical Study

1. Background and project objectives

A medical device clinical study had been neglected due to the original sponsor’s financial difficulties and lack of dedicated clinical resources. The study was later acquired by a new entity, but clinical oversight remained minimal. The Trial Master File existed only as scattered paper documents in file cabinets and boxes, with additional data held by multiple former Contract Research Organizations, third parties, and individuals who had left the project. The study involved 15 clinical sites—13 in the United States and 2 in the European Union—and was entirely paper-based. Most enrolled subjects were approaching their seven-year follow-up visit. The primary objective of the rescue effort was to restore a complete, audit-ready Trial Master File that complied with Good Clinical Practice guidelines and regulatory expectations, while re-establishing active site monitoring, subject follow-up, and overall study compliance to allow continuation without regulatory risk.

2. Key challenges encountered

Critical documents were missing or scattered across multiple physical and digital locations, including server sub-folders with no organized structure. Many documents were held by third parties, former CROs, or individuals who had changed positions, moved companies, or whose contracts had been dissolved, making retrieval extremely difficult. There was no existing organized Trial Master File, and site monitoring had been completely absent. Subject follow-up was incomplete, and data collection had stalled. These issues created significant regulatory, clinical, and quality non-conformities at both the sponsor level and across all 15 study sites. The paper-based nature of the study further complicated organization, tracking, and audit readiness, while the need to reinitiate communication with the FDA added urgency and complexity to the rescue process.

3. Strategic rescue approach

Leadership was assumed as acting Vice President of Regulatory and Clinical Affairs to serve as the sponsor’s dedicated clinical department. A chronological timeline was created to identify all key document holders and map the history of document custody. The Trial Master File reference model was adapted specifically for the medical device study to meet upcoming audit needs. An electronic Trial Master File reference model was developed as the foundation for the final organized file, along with a separate “Holding Tank” electronic model to facilitate secure document exchange during the rehabilitation phase. A cross-functional Clinical Team was assembled, including a Clinical Project Manager, Data Manager, Clinical Trial Assistant, an EU-based Clinical Monitor, and an EU-based Clinical and Regulatory Consultant. All team members received targeted training on document locations, required explanations for certain files, and best practices for maintaining consistency ahead of the FDA audit.

4. Detailed reconstruction and quality control steps

A comprehensive audit and gap analysis were performed across all existing materials. The Clinical Trial Assistant led the hands-on reconstruction by populating physical binders with all sponsor-required documents according to the adapted reference model, creating detailed tables of contents, and sharing data online with site monitors to collaboratively identify gaps. Memos-to-file were written for any unrecoverable documents to document the rationale and mitigation steps. Paper documents were systematically collected, organized, and cross-referenced. All subject data were verified to ensure collection aligned precisely with the study protocol. Site communication was fully restored, with encouragement for subjects to return for overdue follow-up visits. Lost subjects were accounted for through documented efforts. All collected data were submitted to the data-management Contract Research Organization in preparation for database lock. Quality control checks were performed continuously to maintain accuracy and completeness throughout the reconstruction.

5. Regulatory restoration and compliance measures

Active communication with the FDA was reinitiated immediately to demonstrate proactive compliance efforts. Qualified clinical monitors were identified and assigned to re-establish site monitoring and ensure ongoing regulatory adherence at every location. The entire process adhered strictly to ICH E6 Good Clinical Practice guidelines. The reconstructed Trial Master File was prepared specifically for regulatory scrutiny, including support for potential FDA audit activities. On-site support was provided during the final preparation phase to ensure consistency and readiness.

6. Timeline and efficiency measures

The rescue effort was executed efficiently despite the complexity of coordinating multiple legacy sources and stakeholders. Document collection, organization, gap closure, and quality control were completed within a compressed timeframe that allowed the study to regain momentum. Use of electronic holding models and online data sharing accelerated collaboration between the central team and site monitors. Prior experience with similar multi-site device studies informed streamlined workflows, reducing redundant efforts while maintaining rigorous compliance standards.

7. Outcomes and long-term benefits

The Trial Master File was fully reconstructed and restored to an audit-ready state, resolving all identified gaps and non-conformities. The clinical study was successfully brought back on track, with restored site monitoring, completed subject follow-up activities, and data prepared for database lock. The sponsor gained a compliant, organized Trial Master File that mitigated previous regulatory risks and supported continued study operations through the seven-year follow-up period. The project demonstrated effective rescue of a severely neglected clinical program, restored full Good Clinical Practice compliance, and provided a robust foundation for future regulatory interactions and study milestones. The approach minimized disruption while delivering a high-quality, inspection-ready Trial Master File that strengthened overall study integrity and data reliability.